FDA clears CellaVision's automated cell locating device:
This article was originally published in Clinica
Executive Summary
Sweden's CellaVision has received US FDA 510(k) marketing clearance for its automated cell-locating device for the differential count of white blood cells and the characterisation of red morphology. The DiffMaster Octavia system is expected to go on sale during 2002, says Yvonne Martensson, CEO of the Lund-based, Sweden company.